[
  {
    "ts": null,
    "headline": "Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit",
    "summary": "Vaxcyte (NASDAQ:PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company’s pneumococcal conjugate vaccine (PCV) pipeline, with a particular focus on its 31-valent candidate, VAX-31, and the Phase 3 adult program now underway. Focus on pneumococcal co",
    "url": "https://finnhub.io/api/news?id=52d0d7b3f439fe554abb21c7602a14536f5bbe47b1b0c032c2011900ab9cb0cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771099341,
      "headline": "Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit",
      "id": 139101057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Vaxcyte (NASDAQ:PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company’s pneumococcal conjugate vaccine (PCV) pipeline, with a particular focus on its 31-valent candidate, VAX-31, and the Phase 3 adult program now underway. Focus on pneumococcal co",
      "url": "https://finnhub.io/api/news?id=52d0d7b3f439fe554abb21c7602a14536f5bbe47b1b0c032c2011900ab9cb0cd"
    }
  },
  {
    "ts": null,
    "headline": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
    "summary": "These two stocks have historically zigged when the market has zagged.",
    "url": "https://finnhub.io/api/news?id=8643bcd8ef9f05855871cbb70ca96efacb6aa2babc8d5c2fc67ea7b841242b23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771076100,
      "headline": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
      "id": 139095701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These two stocks have historically zigged when the market has zagged.",
      "url": "https://finnhub.io/api/news?id=8643bcd8ef9f05855871cbb70ca96efacb6aa2babc8d5c2fc67ea7b841242b23"
    }
  },
  {
    "ts": null,
    "headline": "How To Retire On $500,000 With A Near-Perfect Portfolio",
    "summary": "The Near-Perfect Strategy portfolio targets 5% income and S&P 500-beating returns with lower volatility. Learn more about the portfolio here.",
    "url": "https://finnhub.io/api/news?id=610ce781d202a0178c8990ae1e035a85394022f68ab08e997714b4f5ace7bc95",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771056900,
      "headline": "How To Retire On $500,000 With A Near-Perfect Portfolio",
      "id": 139095223,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2185337728/image_2185337728.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "The Near-Perfect Strategy portfolio targets 5% income and S&P 500-beating returns with lower volatility. Learn more about the portfolio here.",
      "url": "https://finnhub.io/api/news?id=610ce781d202a0178c8990ae1e035a85394022f68ab08e997714b4f5ace7bc95"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s KEYTRUDA Wins New Ovarian Cancer Use As Valuation Gap Persists",
    "summary": "Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination therapies for platinum-resistant ovarian cancer. The approvals include a companion diagnostic to help identify patients who are eligible for these PD-1 inhibitor based treatments. Merck also entered a collaboration to develop an intravaginal drug delivery platform focused on women's health therapies. For investors watching NYSE:MRK, these approvals and the new delivery...",
    "url": "https://finnhub.io/api/news?id=f8851f889f09d35353e233e6d162895e0f3104ae6d071f9ecbc3e340edb6c56e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771043193,
      "headline": "Merck’s KEYTRUDA Wins New Ovarian Cancer Use As Valuation Gap Persists",
      "id": 139093133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination therapies for platinum-resistant ovarian cancer. The approvals include a companion diagnostic to help identify patients who are eligible for these PD-1 inhibitor based treatments. Merck also entered a collaboration to develop an intravaginal drug delivery platform focused on women's health therapies. For investors watching NYSE:MRK, these approvals and the new delivery...",
      "url": "https://finnhub.io/api/news?id=f8851f889f09d35353e233e6d162895e0f3104ae6d071f9ecbc3e340edb6c56e"
    }
  }
]